PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Gade, N.* ; Seifert, P.* ; Gerckens, M. ; Mümmler, C. ; Kauke, T.* ; Dick, A.* ; Veit, T.* ; Roden, D.* ; Hoffmann, S.* ; Scherzer, M.* ; Höpler, J.* ; Binzenhöfer, L.* ; Lanz, H.* ; Michel, S.* ; Schneider, C.* ; Irlbeck, M.* ; Tomasi, R.* ; Hatz, R.* ; Hagl, C.* ; Massberg, S.* ; Milger, K.* ; Behr, J.* ; Lüsebrink, E.* ; Kneidinger, N.*

Association of HLA mismatch with adverse cardiovascular events following lung transplantation: A single-center study.

Clin. Transplant. 39:e70157 (2025)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
AIMS: Coronary artery disease (CAD) is a frequent comorbidity in lung transplant (LuTx) candidates. The impact of allogenic organ transplantation and the corresponding alterations in immune response on the progression of CAD remains poorly understood. In this study, we sought to analyze the effect of donor-recipient overall human leukocyte antigen (HLA) and HLA-DQ mismatch on cardiovascular outcomes following LuTx. METHODS AND RESULTS: This retrospective analysis of adult patients receiving lung transplantation at the LMU University Hospital between 2012 and 2018 included 310 patients, the majority of whom (67.4%) had undergone double lung transplantation. There were no significant differences in the incidence of the primary composite endpoint between patients with high/low HLA mismatches (22 [7.9%] vs. 4 [12.9%]; p = 0.311). Numerically higher rates of the primary endpoint, myocardial infarction, and cardiovascular death in the low HLA mismatch group can partially be explained by differences in baseline rates of CAD and coronary sclerosis. Notably, neither HLA-DQ mismatch nor the occurrence of rejection episodes or cytomegalovirus (CMV) infection was associated with the occurrence of cardiovascular events following transplantation. CONCLUSION: In this study cohort, high HLA mismatch and HLA-DQ mismatch were not associated with increased adverse cardiovascular events. Furthermore, neither transplant rejection nor CMV infection increased the risk for cardiovascular events. The high cardiovascular event rates following LuTx necessitate meticulous cardiovascular follow-up, irrespective of immunological matching.
Impact Factor
Scopus SNIP
Altmetric
1.900
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Hla Mismatch ; Anti‐hla Antibodies ; Cardiovascular Evaluation ; Coronary Artery Disease ; Host Versus Graft Antibodies ; Lung Transplantation ; Revascularization ; Transplant Candidate Selection; Bronchiolitis Obliterans Syndrome; Antibody-mediated Rejection; International Society; Candidates; Heart; Restenosis; Prevention; Guidelines; Selection; Survival
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 0902-0063
e-ISSN 1399-0012
Zeitschrift Clinical Transplantation
Quellenangaben Band: 39, Heft: 4, Seiten: , Artikelnummer: e70157 Supplement: ,
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Lung Research
PSP-Element(e) G-501600-001
DOI 10.1111/ctr.70157
WOS ID 001468921400001
Scopus ID 105003425149
PubMed ID 40245267
Erfassungsdatum 2025-05-10
[➜Korrektur melden]